JUNSHI BIO (01877) experienced a significant surge in its stock price during Friday's trading session, soaring by 5.11% as investors reacted positively to the company's recently announced financial results for the first three quarters of 2025.

The biopharmaceutical company reported impressive financial performance, with revenue reaching RMB 1.806 billion, marking a substantial 42.06% increase year-on-year. More notably, JUNSHI BIO's net loss attributable to shareholders narrowed by 35.7% to RMB 596 million, signaling improved operational efficiency. The company's core product, Toripalimab (brand name: Tuoyi®/LOQTORZI®, product code: JS001), played a crucial role in this growth, generating domestic sales of approximately RMB 1.495 billion, up around 40% compared to the same period last year.

The market's enthusiastic response to JUNSHI BIO's financial results reflects investor confidence in the company's growth trajectory and operational improvements. The implementation of cost-control measures and resource optimization under the "efficiency enhancement and shareholder return" initiative has significantly contributed to reducing losses. Furthermore, with cash and tradable financial assets totaling RMB 3.27 billion, JUNSHI BIO maintains a strong liquidity position, providing a solid foundation for future growth and development in the competitive biopharmaceutical sector.